The Effects of Vitamin D Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The current study was conducted to evaluate the effects of vitamin D supplementation on metabolic status of patients with PCOS.

Why It Was Studied

Data on the effects of vitamin D supplementation on metabolic status of patients with polycystic ovary syndrome (PCOS) are scarce.

This randomized double-blind, placebo-controlled trial was performed on 70 vitamin D-deficient (serum concentrations<20 ng/ml) women with phenotype B-PCOS according to the Rotterdam criteria aged 18-40 years old.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Blood Glucose, C-Reactive Protein, Insulin Resistance, Malondialdehyde, Oxidative Stress and Polycystic Ovary Syndrome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2017 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.